Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces

IF 3.9 2区医学 Q1 PSYCHIATRY

Drug and alcohol dependence Pub Date : 2024-09-24 DOI:10.1016/j.drugalcdep.2024.112451

{"title":"Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces","authors":"","doi":"10.1016/j.drugalcdep.2024.112451","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Injectable extended-release buprenorphine (BUP-ER) (Sublocade®) is a newer form of opioid agonist therapy (OAT) administered monthly. It was listed on formularies across Canada in February 2020, expanding the options for OAT across the country. This study describes rates of injectable BUP-ER uptake in five provinces to compare access to this novel medication across Canada.</div></div><div><h3>Methods</h3><div>We conducted a retrospective time-series analysis among individuals who received injectable BUP-ER in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario from February 1, 2020, to March 31, 2022. The primary outcome was the population-adjusted rate of injectable BUP-ER in each province, with secondary analyses exploring rates by urban/rural location, and the number of prescribers of injectable BUP-ER per 100,000 population.</div></div><div><h3>Results</h3><div>In total, 6528 individuals were treated with injectable BUP-ER, with the majority in British Columbia (29.0 %) and Ontario (47.0 %). By March 2022, the rate of BUP-ER use was highest in British Columbia (16.6 per 100,000), and lowest in Ontario (9.1 per 100,000). The rate of BUP-ER use was higher in rural areas (15.5 per 100,000) compared to urban centres (10.6 per 100,000), and British Columbia had the highest rate of prescribers per 100,000 population (5.9) compared to Ontario (2.2), Alberta (2.3), Saskatchewan (3.4) and Manitoba (3.5) by the end of Q1–2022.</div></div><div><h3>Conclusion</h3><div>Uptake of BUP-ER varied geographically since being approved by Health Canada. More rapid uptake in rural areas is reassuring and suggests that this form of OAT may be supporting treatment access to those with barriers to more traditional treatment formulations.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871624013760","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Injectable extended-release buprenorphine (BUP-ER) (Sublocade®) is a newer form of opioid agonist therapy (OAT) administered monthly. It was listed on formularies across Canada in February 2020, expanding the options for OAT across the country. This study describes rates of injectable BUP-ER uptake in five provinces to compare access to this novel medication across Canada.

Methods

We conducted a retrospective time-series analysis among individuals who received injectable BUP-ER in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario from February 1, 2020, to March 31, 2022. The primary outcome was the population-adjusted rate of injectable BUP-ER in each province, with secondary analyses exploring rates by urban/rural location, and the number of prescribers of injectable BUP-ER per 100,000 population.

Results

In total, 6528 individuals were treated with injectable BUP-ER, with the majority in British Columbia (29.0 %) and Ontario (47.0 %). By March 2022, the rate of BUP-ER use was highest in British Columbia (16.6 per 100,000), and lowest in Ontario (9.1 per 100,000). The rate of BUP-ER use was higher in rural areas (15.5 per 100,000) compared to urban centres (10.6 per 100,000), and British Columbia had the highest rate of prescribers per 100,000 population (5.9) compared to Ontario (2.2), Alberta (2.3), Saskatchewan (3.4) and Manitoba (3.5) by the end of Q1–2022.

Conclusion

Uptake of BUP-ER varied geographically since being approved by Health Canada. More rapid uptake in rural areas is reassuring and suggests that this form of OAT may be supporting treatment access to those with barriers to more traditional treatment formulations.

查看原文本刊更多论文

加拿大注射用丁丙诺啡处方的趋势：加拿大五个省的描述性分析

背景注射用缓释丁丙诺啡（BUP-ER）（Sublocade®）是一种较新的阿片激动剂疗法（OAT），每月给药一次。它于 2020 年 2 月被列入加拿大全国的处方集，从而扩大了全国范围内 OAT 的选择范围。本研究描述了五个省份的注射用 BUP-ER 使用率，以比较加拿大各地获得这种新型药物的情况。方法我们对 2020 年 2 月 1 日至 2022 年 3 月 31 日期间不列颠哥伦比亚省、艾伯塔省、萨斯喀彻温省、马尼托巴省和安大略省接受注射用 BUP-ER 的个人进行了回顾性时间序列分析。主要结果是各省经人口调整后的注射用 BUP-ER 使用率，次要分析包括城市/农村地区的使用率，以及每 10 万人口中注射用 BUP-ER 的处方者数量。截至 2022 年 3 月，不列颠哥伦比亚省的 BUP-ER 使用率最高（每 10 万人中有 16.6 人使用），安大略省最低（每 10 万人中有 9.1 人使用）。到 2022 年第一季度末，BUP-ER 在农村地区的使用率（每 100,000 人中有 15.5 人）高于城市中心（每 100,000 人中有 10.6 人），不列颠哥伦比亚省每 100,000 人中的处方者比例最高（5.9 人），而安大略省（2.2 人）、艾伯塔省（2.3 人）、萨斯喀彻温省（3.4 人）和马尼托巴省（3.5 人）的处方者比例最低。令人欣慰的是，农村地区的吸收速度更快，这表明这种形式的 OAT 可能有助于那些在接受更传统的治疗配方方面存在障碍的人获得治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug and alcohol dependence 医学-精神病学

CiteScore

7.40

自引率

7.10%

发文量

409

审稿时长

41 days

期刊介绍： Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.